Metsera, Inc.
MTSR
Clasificación en acciones
#2571
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Precio por acción
$70.50
Última sincronización: 2025-11-14
Capitalización bursátil
$7.33B
Cambio (1 día)
0.00%
Cambio (1 año)
33.60%
País
US
Comercio Metsera, Inc. (MTSR)
Categoría
Healthcare
Historial del precio de la acción de Metsera, Inc. (MTSR)
Precio más alto de cierre: $72.34 el 2025-11-01
Precio más bajo de cierre: $26.50 el 2025-01-01
Precio más bajo de cierre: $26.50 el 2025-01-01
Historial del precio de la acción de Metsera, Inc. desde 2025 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2026 (TTM) | -10.54% |
| 2025 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $765.49 | 8.80% |
CH
|
